Medical Condition News

RSS

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).

19 Feb 2014

DFTD study explains how human selection alters evolution of cancerous cells

Tasmanian Devil Facial Tumour Disease (DFTD) has ravaged the world's largest carnivorous marsupial since it emerged in 1996, resulting in a population decline of over 90%.

19 Feb 2014

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

By 2020, nearly 80 million people are expected to have glaucoma, a disorder of the eye that, if left untreated, can damage the optic nerve and eventually lead to blindness.

19 Feb 2014

Researchers discover protein for treatment of anaplastic thyroid carcinoma

Anaplastic thyroid carcinoma (ATC) is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore (NUS) have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.

19 Feb 2014

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.

19 Feb 2014

Study: 85% of patients who have heart attacks after surgery do not experience traditional symptoms

Without administering a simple blood test in the first few days after surgery, 85 percent of the heart attacks or injuries patients suffer could be missed, according to a study in the March issue of Anesthesiology.

19 Feb 2014

COPD sufferers can reduce risk of being hospitalized by walking 3 kilometers a day

New research in Respirology shows that suffers of Chronic obstructive pulmonary disease (COPD) can reduce their risk of being hospitalized with severe attacks, by maintaining an exercise regime of walking between three to six kilometers a day.

19 Feb 2014

Researchers find new ways to elucidate creation of toxic oligomers associated with Alzheimer's disease

Researchers studying peptides using the Gordon supercomputer at the San Diego Supercomputer Center (SDSC) at the University of California, San Diego (UCSD) have found new ways to elucidate the creation of the toxic oligomers associated with Alzheimer's disease.

19 Feb 2014

A non-invasive method developed to fight heart disease

Clemson University researchers have developed nanoparticles that can deliver drugs targeting damaged arteries, a non-invasive method to fight heart disease.

18 Feb 2014

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Tel Aviv University researchers won two out of three prestigious melanoma research awards granted this year by The Melanoma Research Alliance and The Saban Family Foundation. The Team Science Awards are the centerpiece of the MRA research fund, which seeks to promote transformational melanoma research for swift clinical implementation.

18 Feb 2014

Discovery could lead to improved early detection, prevention strategies for sudden cardiac death

UC Irvine researchers have found a specific genetic flaw that is connected to sudden death due to heart arrhythmia - a leading cause of mortality for adults around the world.

18 Feb 2014

Scientists develop mathematical method for classifying forms of glioblastoma

Scientists at The Wistar Institute have developed a mathematical method for classifying forms of glioblastoma, an aggressive and deadly type of brain cancer, through variations in the way these tumor cells "read" genes. Their system was capable of predicting the subclasses of glioblastoma tumors with 92 percent accuracy. With further testing, this system could enable physicians to accurately predict which forms of therapy would benefit their patients the most.

18 Feb 2014

Pathway Genomics announces launch of Hereditary Colorectal Cancer DNA Insight genetic test

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced the launch of Hereditary Colorectal Cancer DNA Insight, the company's premier hereditary cancer genetic test. Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient's risk of developing certain types of cancer.

18 Feb 2014

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).

18 Feb 2014

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

Update Pharma Inc. today announced that the FDA has approved Orphan Drug Status for the use of UPI-928 for the treatment of Acute Myeloid Leukemia (AML).

18 Feb 2014

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.

18 Feb 2014

Medical Condition News

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

DFTD study explains how human selection alters evolution of cancerous cells

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

Researchers discover protein for treatment of anaplastic thyroid carcinoma

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

Study: 85% of patients who have heart attacks after surgery do not experience traditional symptoms

COPD sufferers can reduce risk of being hospitalized by walking 3 kilometers a day

Researchers find new ways to elucidate creation of toxic oligomers associated with Alzheimer's disease

A non-invasive method developed to fight heart disease

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Discovery could lead to improved early detection, prevention strategies for sudden cardiac death

Scientists develop mathematical method for classifying forms of glioblastoma

Pathway Genomics announces launch of Hereditary Colorectal Cancer DNA Insight genetic test

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Samoa Island harbors a global health mystery that could predict obesity crisis

Study reveals overall success rate of AF ablation in Europe

High levels of stress hormone cortisol may contribute to risk aversion in traders

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News